Jeffrey M Holzbeierlein

Summary

Affiliation: University of Kansas Medical Center
Country: USA

Publications

  1. doi request reprint Hsp90: a drug target?
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Hospital, 3901 Rainbow Boulevard, Mail Stop 3016, Kansas, KS, 66160, USA
    Curr Oncol Rep 12:95-101. 2010
  2. ncbi request reprint Complications of androgen-deprivation therapy for prostate cancer
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3016, Kansas City, KS 66160, USA
    Clin Prostate Cancer 2:147-52. 2003
  3. ncbi request reprint Complications of androgen deprivation therapy: prevention and treatment
    Jeffrey M Holzbeierlein
    University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Oncology (Williston Park) 18:303-9; discussion 310, 315, 319-21. 2004
  4. ncbi request reprint Complications of androgen deprivation therapy for prostate cancer
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, Kansas City, 66160, USA
    Curr Opin Urol 14:177-83. 2004
  5. ncbi request reprint What effect does androgen suppression therapy have on frequency and timing of fatal myocardial infarctions?
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Hospital, Kansas City, KS 66160, USA
    Nat Clin Pract Oncol 5:74-5. 2008
  6. ncbi request reprint The craft of urologic surgery: modern radical perineal prostatectomy
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3016, Kansas City, KS 66160, USA
    Urol Clin North Am 31:629-41, xi-xii. 2004
  7. ncbi request reprint The role of soy phytoestrogens in prostate cancer
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Curr Opin Urol 15:17-22. 2005
  8. ncbi request reprint Managing complications of androgen deprivation therapy for prostate cancer
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Urol Clin North Am 33:181-90, vi. 2006
  9. pmc Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors
    Takrima Sadikot
    1 University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas
    Assay Drug Dev Technol 11:478-88. 2013
  10. pmc Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial
    Jill M Hamilton-Reeves
    Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, Kansas, USA
    PLoS ONE 8:e68331. 2013

Collaborators

Detail Information

Publications24

  1. doi request reprint Hsp90: a drug target?
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Hospital, 3901 Rainbow Boulevard, Mail Stop 3016, Kansas, KS, 66160, USA
    Curr Oncol Rep 12:95-101. 2010
    ..In addition, to the N-terminal site of Hsp90, the C-terminal site appears to be another target for inhibition of Hsp90. More recently, inhibitors of the C terminus of Hsp90 have been developed and studied in vitro with promising results...
  2. ncbi request reprint Complications of androgen-deprivation therapy for prostate cancer
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3016, Kansas City, KS 66160, USA
    Clin Prostate Cancer 2:147-52. 2003
    ..Patients and physicians should be well aware of the potential side effects of androgen-deprivation therapy as well as the preventive and treatment strategies for these side effects in order to improve patients quality of life and health...
  3. ncbi request reprint Complications of androgen deprivation therapy: prevention and treatment
    Jeffrey M Holzbeierlein
    University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Oncology (Williston Park) 18:303-9; discussion 310, 315, 319-21. 2004
    ..This review focuses on the wide range of side effects associated with androgen ablation as well as preventive and treatment strategies...
  4. ncbi request reprint Complications of androgen deprivation therapy for prostate cancer
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, Kansas City, 66160, USA
    Curr Opin Urol 14:177-83. 2004
    ..Within the last decade, however, there has been a significant increase in its use. Therefore, it is incumbent upon the physician to be familiar with the side effects associated with this treatment...
  5. ncbi request reprint What effect does androgen suppression therapy have on frequency and timing of fatal myocardial infarctions?
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Hospital, Kansas City, KS 66160, USA
    Nat Clin Pract Oncol 5:74-5. 2008
  6. ncbi request reprint The craft of urologic surgery: modern radical perineal prostatectomy
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3016, Kansas City, KS 66160, USA
    Urol Clin North Am 31:629-41, xi-xii. 2004
    ..As discussed in this article, RPP offers several advantages over the retropubic or laparoscopic approach for certain patients...
  7. ncbi request reprint The role of soy phytoestrogens in prostate cancer
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Curr Opin Urol 15:17-22. 2005
    ..One hypothesis for this reduction in prostate cancer deaths is due to the difference in soy consumption. The purpose of this paper is to review the effects of soy at the molecular level as well as to review the in-vivo effects...
  8. ncbi request reprint Managing complications of androgen deprivation therapy for prostate cancer
    Jeffrey M Holzbeierlein
    Department of Urology, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Urol Clin North Am 33:181-90, vi. 2006
    ..This article describes the potential complications of ADT and the recommendations for treatment or prevention of these complications. In addition,we examine the role of nontraditional forms of ADT and the potential benefits they offer...
  9. pmc Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors
    Takrima Sadikot
    1 University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City, Kansas
    Assay Drug Dev Technol 11:478-88. 2013
    ..Here, we report the development of an in-cell Hsp90-dependent luciferase refolding assay that is amenable across cancer cell lines for the screening of inhibitors in their specific milieu...
  10. pmc Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial
    Jill M Hamilton-Reeves
    Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City, Kansas, USA
    PLoS ONE 8:e68331. 2013
    ..We describe the effects of soy isoflavone consumption on prostate specific antigen (PSA), hormone levels, total cholesterol, and apoptosis in men with localized prostate cancer...
  11. pmc Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells
    Jeffery D Eskew
    The University of Kansas Cancer Center, The University of Kansas Medical Center, Kansas City, KS 66160, USA
    BMC Cancer 11:468. 2011
    ....
  12. doi request reprint Cancer immunotherapy: a paradigm shift for prostate cancer treatment
    Dev Karan
    Department of Urology, University of Kansas Medical Center, Kansas City, 3901 Rainbow Boulevard, Kansas City, KS 66106, USA
    Nat Rev Urol 9:376-85. 2012
    ....
  13. ncbi request reprint A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients
    Paul R Womble
    Department of Urology, University of Kansas Hospital, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    J Urol 186:882-7. 2011
    ..Looking for improvement on these outcomes, we conducted a phase II clinical trial examining the combination of ketoconazole and docetaxel in the neoadjuvant setting before radical prostatectomy...
  14. ncbi request reprint Active surveillance for prostate cancer in a veteran population
    Eugene K Lee
    Department of Urology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Can J Urol 17:5429-35. 2010
    ..We review our experience with active surveillance in a veteran population...
  15. ncbi request reprint Management of the contralateral testicle in patients with unilateral testicular cancer
    Eugene K Lee
    University of Kansas Medical Center, Kansas City, KS 66160, USA
    World J Urol 27:421-6. 2009
    ..In this review we present the arguments for and against a biopsy of the contralateral testicle, review the techniques of biopsy as well as its complications, and discuss the interventions employed to prevent CIS from progressing...
  16. ncbi request reprint Evaluation of ureterointestinal anastomosis: Wallace vs Bricker
    Apostolos Evangelidis
    Department of Urology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    J Urol 175:1755-8; discussion 1758. 2006
    ..There are no published reports to our knowledge comparing the complication rates of the 2 most frequently used ureterointestinal anastomoses. We compared the Bricker method vs the Wallace method in terms of stricture rate...
  17. doi request reprint Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice
    Dev Karan
    Veterans Affairs Medical Center, Kansas City, MO, USA
    Immunotherapy 3:735-46. 2011
    ..We used this adenovirus vector to test the concept that multiantigenic effector T cells could be generated simultaneously following a single immunization...
  18. doi request reprint Prostate imaging modalities that can be used for complementary and alternative medicine clinical studies
    Reginald W Dusing
    Division of Nuclear Medicine, Department of Radiology, Kansas University Medical Center, MS 4032, 3901 Rainbow Boulevard, Kansas City, KS 66160 7234, USA
    Urol Clin North Am 38:343-57. 2011
    ..This article presents case studies of PET scanning using carbon 11 acetate and discusses intravenously infused ascorbate, a complementary and alternative medicine therapy for prostate cancer...
  19. doi request reprint The perioperative management of an inferior vena caval tumor thrombus in patients with renal cell carcinoma
    Daniel Y Woodruff
    Department of Urology, University of Kansas, Kansas City, KS 66160, USA
    Urol Oncol 31:517-21. 2013
    ..Our goal was to define the optimal management of patients with RCC and IVC-TT...
  20. pmc Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells
    Shawna B Matthews
    Department of Urology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
    Prostate 70:27-36. 2010
    ..We now report the characterization of the novel novobiocin analogue, F-4, which demonstrates improved cytotoxicity in prostate cancer cell lines compared to the N-terminal inhibitor, 17-AAG...
  21. ncbi request reprint Adjuvant radiation therapy after radical prostatectomy: when is it indicated?
    Stephen M Graham
    Department of Urology, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Curr Urol Rep 10:194-8. 2009
    ..The decision to use ART should be based on the patient's pathological characteristics, clinical status, side effects, and open communication between the patient and provider...
  22. ncbi request reprint Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th Street, New York, NY 10021, USA
    J Urol 172:878-81. 2004
    ..This study analyzes the outcomes of partial cystectomy in a contemporary cohort of patients to identify appropriate selection criteria for the procedure...
  23. ncbi request reprint Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice
    Manlio A Goetzl
    Department of Urology, University of Kansas Medical Center, Kansas City, KS 66160, USA
    Nat Clin Pract Urol 3:422-9. 2006
    ..This review summarizes the PCPT, analyzes its controversial results, and describes future prostate cancer chemoprevention studies...
  24. ncbi request reprint Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 169:2122-5. 2003
    ..The optimal management of bilateral testicular tumors continues to evolve. We examined the incidence, characteristics, histology, treatment and clinical outcomes of patients with bilateral testicular cancer...